Novel pharmacological agents are under development to treat mitochondrial disease.

There is an emerging field of non-pharmacological treatments that have not been comprehensively reviewed in the literature.

Rigorous randomised control trials with objective patient-centred primary outcomes are required to establish evidence-based guidelines.